Literature DB >> 22214759

Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications.

Beate Wieseler1, Michaela F Kerekes, Volker Vervoelgyi, Natalie McGauran, Thomas Kaiser.   

Abstract

OBJECTIVE: To investigate to what extent three types of documents for reporting clinical trials provide sufficient information for trial evaluation.
DESIGN: Retrospective analysis DATA SOURCES: Primary studies and corresponding documents (registry reports, clinical study reports, journal publications) from 16 health technology assessments of drugs conducted by the German Institute for Quality and Efficiency in Health Care between 2006 and February 2011. Data analysis We assessed reporting quality for each study and each available document for six items on methods and six on outcomes, and dichotomised them as "completely reported" or "incompletely reported." For each document type, we calculated the proportion of studies with complete reporting for methods and outcomes, per item and overall, and compared the findings.
RESULTS: We identified 268 studies. Publications, study reports and registry reports were available for 192 (72%), 101 (38%), and 78 (29%) studies, respectively. Reporting quality was highest in study reports, which overall provided complete information for 90% of items (1086/1212). Registry reports provided more complete information on outcomes than on methods (overall 330/468 (71%) v 147/468 (31%)); the same applied to publications (594/1152 (52%) v 458/1152 (40%)). In the matched pairs analysis, reporting quality was poorer in registry reports than in study reports for overall methods and outcomes (P<0.001 in each case). Compared with publications, reporting quality was poorer in registry reports for overall methods (P<0.001), but better for outcomes (P=0.005).
CONCLUSION: Registry reports and publications insufficiently report clinical trials but may supplement each other. Measures to improve reporting include the mandatory worldwide implementation of adequate standards for results registration.

Entities:  

Mesh:

Year:  2012        PMID: 22214759     DOI: 10.1136/bmj.d8141

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  39 in total

Review 1.  The evolution in registration of clinical trials: a chronicle of the historical calls and current initiatives promoting transparency.

Authors:  Claudia Pansieri; Chiara Pandolfini; Maurizio Bonati
Journal:  Eur J Clin Pharmacol       Date:  2015-08-05       Impact factor: 2.953

2.  Use of data from registered clinical trials to identify gaps in health research and development.

Authors:  Roderik F Viergever; Robert F Terry; Ghassan Karam
Journal:  Bull World Health Organ       Date:  2013-04-03       Impact factor: 9.408

3.  Secrecy or transparency? The future of regulatory trial data.

Authors:  Beate Wieseler; Natalie McGauran
Journal:  CMAJ       Date:  2016-11-14       Impact factor: 8.262

4.  Clinical applicability of natural products for prevention and treatment of oral mucositis: a systematic review and meta-analysis.

Authors:  Ingrid Carla Guedes da Silva Lima; Laura de Fátima Souto Maior; Luiz Alcino Monteiro Gueiros; Jair Carneiro Leão; Jane Sheila Higino; Alessandra Albuquerque Tavares Carvalho
Journal:  Clin Oral Investig       Date:  2021-01-07       Impact factor: 3.573

5.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

6.  Time to ensure that clinical trial appropriate results are actually published.

Authors:  Rafael Dal-Ré; Arthur L Caplan
Journal:  Eur J Clin Pharmacol       Date:  2014-01-11       Impact factor: 2.953

7.  Increasing value and reducing waste: addressing inaccessible research.

Authors:  An-Wen Chan; Fujian Song; Andrew Vickers; Tom Jefferson; Kay Dickersin; Peter C Gøtzsche; Harlan M Krumholz; Davina Ghersi; H Bart van der Worp
Journal:  Lancet       Date:  2014-01-08       Impact factor: 79.321

8.  SPIRIT 2013 Statement: defining standard protocol items for clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Douglas G Altman; Andreas Laupacis; Peter C Gøtzsche; Karmela Krle A-Jerić; Asbjørn Hrobjartsson; Howard Mann; Kay Dickersin; Jesse A Berlin; Caroline J Dore; Wendy R Parulekar; William S M Summerskill; Trish Groves; Kenneth F Schulz; Harold C Sox; Frank W Rockhold; Drummond Rennie; David Moher
Journal:  Rev Panam Salud Publica       Date:  2015-12

9.  SPIRIT 2013 statement: defining standard protocol items for clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Douglas G Altman; Andreas Laupacis; Peter C Gøtzsche; Karmela Krleža-Jerić; Asbjørn Hróbjartsson; Howard Mann; Kay Dickersin; Jesse A Berlin; Caroline J Doré; Wendy R Parulekar; William S M Summerskill; Trish Groves; Kenneth F Schulz; Harold C Sox; Frank W Rockhold; Drummond Rennie; David Moher
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391

10.  Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.

Authors:  Sophie Juul; Faiza Siddiqui; Marija Barbateskovic; Caroline Kamp Jørgensen; Michael Pascal Hengartner; Irving Kirsch; Christian Gluud; Janus Christian Jakobsen
Journal:  Syst Rev       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.